Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides

Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) is an investigational cell therapy designed for the treatment of autoimmune diseases such as multiple sclerosis. This therapy involves generating patient-specific (autologous) dendritic cells from peripheral blood monocytes and inducing them into a tolerogenic state using 1,25-dihydroxyvitamin D3 (the active form of vitamin D3). These modified dendritic cells are then loaded with disease-relevant autoantigens—specifically, myelin peptides—to promote antigen-specific immune tolerance. The mechanism centers on reducing pathogenic T cell responses by inhibiting T cell proliferation, shifting the immune response toward an anti-inflammatory Th2 profile, and promoting regulatory T cell differentiation. Clinical trials have focused on safety and feasibility in multiple sclerosis patients[1][2][4][5][6][7].

Other names

VitD3-tolDCVitD-3-tolDCVitD 3-tolDCvitamin D3-induced tolerogenic dendritic cellsautologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides